Publikationen von 0000-0002-2485-1796
(ORCID: 0000-0002-2485-1796)

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke , Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert , Weller, Johannes , Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh , Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin und Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. Journal of Neuro-Oncology 144 (3), S. 501-509. Volltext nicht vorhanden.

Weller, Johannes , Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert , Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich und Schäfer, Niklas (2019) Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology 20 (10), S. 1444-1453. Volltext nicht vorhanden.

Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter , Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh , Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert , Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes , Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang , Weller, Michael , Fimmers, Rolf, Schmid, Matthias , Hattingen, Elke , Pietsch, Torsten, Coch, Christoph und Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet 393 (10172), S. 678-688. Volltext nicht vorhanden.

Hutterer, Markus , Ebner, Yvonne, Riemenschneider, Markus J., Willuweit, Antje , McCoy, Mark, Egger, Barbara, Schröder, Michael, Wendl, Christina, Hellwig, Dirk, Grosse, Jirka, Menhart, Karin, Proescholdt, Martin, Fritsch, Brita, Urbach, Horst, Stockhammer, Guenther, Roelcke, Ulrich, Galldiks, Norbert , Meyer, Philipp T., Langen, Karl-Josef , Hau, Peter und Trinka, Eugen (2016) Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18 F-Fluoroethyl-l-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. Journal of Nuclear Medicine 58 (1), S. 129-137. Volltext nicht vorhanden.

Galldiks, Norbert , Dunkl, Veronika, Stoffels, Gabriele , Hutterer, Markus, Rapp, Marion, Sabel, Michael, Reifenberger, Guido, Kebir, Sied, Dorn, Franziska, Blau, Tobias, Herrlinger, Ulrich, Hau, Peter, Ruge, Maximilian I., Kocher, Martin, Goldbrunner, Roland, Fink, Gereon R. , Drzezga, Alexander, Schmidt, Matthias und Langen, Karl-Josef (2015) Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET. European Journal of Nuclear Medicine and Molecular Imaging 42 (5), S. 685-695. Volltext nicht vorhanden.